

FORM 7
MONTHLY PROGRESS REPORT

October 2021

Name of Listed Issuer: OVATION SCIENCE INC. (the "Issuer" or the "Company").

Trading Symbol: **OVAT**

Number of Outstanding Listed Securities: **29,374,836**

Date: **November 4, 2021**

(for the month of October 2021)

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Ovation Science is an innovative drug development company with a high performance patented topical and transdermal delivery system called Invisicare® which enhances the delivery of ingredients to and through the skin. Using pharmaceutical drug development protocols and innovation, Ovation Science has developed topical and transdermal product formulations; all delivered by Invisicare®.

Our unique formulations are licensed to companies that are branding experts that manufacture and market these products. Due to unprecedented demand caused by the coronavirus (COVID-19) pandemic the Company has introduced its unique DermSafe® hand sanitizer product in Canada as the product has Health Canada approval and has exported to other countries including China, UK and Mexico. In the US, the Company has its research and development laboratory which develops product formulations using Cannabis (CBD and CBD/THC topical formulations). Presently the Company has a licensee selling our CBD/THC formulations in Nevada online and through state-approved dispensaries.

2. Provide a general overview and discussion of the activities of management.

Ovation sells and licenses its highly effective health and wellness products globally in two distinct categories including (1) topical/ transdermal cannabis products and (2) DermSafe®; the Company's unique hand sanitizer without alcohol that is helping fight the battle against COVID-19 globally.

Ovation Science Inc. has seen an increase in the sale of its non-alcohol hand sanitizer lotion, DermSafe, to professional and amateur athletes across Canada. Whether it's for athletes travelling locally or internationally or local junior baseball or any teams, the benefit of using a non-alcohol hand sanitizer is resonating. Consumers are tired of drying out their hands with alcohol and the Company's is a desirable alternative.

With the re-opening up of the economy and increased tourism back to Nevada and across the country, cannabis sales are growing. The Company reported a record increase in royalty income from its licensee in Nevada for January 2021. The opportunity in the USA continues to grow, with 38 states, plus US Virgin Islands, Puerto Rico, District of Columbia and Guam approving the sale of cannabis. Along with focusing on expanding in the USA, the Company is also seeking additional licensees for other countries including Canada and those approved countries in the EU.

The Company's second product category is DermSafe® hand sanitizing lotion. This product was introduced as the pandemic started as the need for non-alcohol hand sanitizers was apparent. An independent study successfully proved the effectiveness of DermSafe hand sanitizer lotion against a human coronavirus (beta coronavirus strain OC43), a surrogate for SARS-CoV-2 (the virus that causes COVID-19). The results of the controlled laboratory testing showed that DermSafe demonstrated a 99.97-per-cent reduction in active viral loads at two time points. Additionally, DermSafe has received the seal of approval from the Dermatology Review Panel (DRP). DRP is a panel of Canadian dermatologists that provide an independent review of scientific data for non-prescription products in order to authenticate a product's claims. Notable national brands including shampoo, laundry soap, diapers, skin care and other products have received this distinction

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None

4. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

FORM 7 – MONTHLY PROGRESS REPORT

7. Describe the acquisition of new customers or loss of customers.
- None**
8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
- None.**
9. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.
- None**
10. Report on any labour disputes and resolutions of those disputes if applicable.
- Not applicable.**
11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
- Not applicable**
12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
- None**
13. Provide details of any securities issued and options or warrants granted.
- None**
14. Provide details of any loans to or by Related Persons.
- None**
15. Provide details of any changes in directors, officers or committee members.
- None**
16. Discuss any trends, which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

In March 2020, the World Health Organization declared the recent outbreak of coronavirus, also known as "COVID-19", a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. The impact on the Company is

not currently fully determinable and management continues to monitor the situation.

For Ovation, COVID-19 has had both positive and negative effects on its business.

The Company's DermSafe product, which has completed studies verifying its ability to kill both bacteria and envelope viruses like H1N1 (swine flu) and H5N1 (bird flu). COVID-19 is also an envelope virus. Hand sanitizers have seen a surge in demand. However materials like bottles, caps and raw ingredients are much harder to obtain because of the worldwide demand for these arising from the COVID-19 pandemic. There is also strong competition for these items as many traditional alcohol hand sanitizers use similar packaging. Ovation has been diligent in acquiring inventory to help mitigate this issue.

Due to the mandatory closure of non-essential retail stores and dispensaries in the US there has been a significant decrease in sales in the cannabis market in Q1 and 2 of 2020. The Company however has seen an increase in sales of the Ovation formulated Baskin CBD products that are sold in Nevada state dispensaries in Q3 and Q4 of 2020 and Q1 2021 by its licensee.

DermSafe sales has made up for the slowdown in CBD product sales and the Company currently anticipates an overall increase in revenue.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **November 4, 2021**

Terry Howlett

Director or Senior Officer



Signature

President

Official Capacity

Issuer Details Name of Issuer Ovation Science Inc	For Month End October 2021	Date of Report November 4, 2021
Issuer Address SUITE 1140-625 Howe Street		
City/Province/Postal Code Vancouver, BC, V6C 2T6	Issuer Fax No.	Issuer Telephone No. 604-283-0903
Contact Name TERRY HOWLETT	Contact Position PRESIDENT	Contact Telephone No. 604-283-0903
Contact Email Address info@ovationscience.com	Web Site Address www.ovationscience.com	